Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

Glycogen Storage Disease Type II (Pompe Disease) is a rare, progressive lysosomal storage disorder caused by deficient acid alpha-glucosidase (GAA) activity, resulting in lysosomal glycogen accumulation and predominantly affecting skeletal, respiratory and cardiac muscle. The estimated incidence of Pompe disease is approximately 1 in 40,000 live births, although incidence varies substantially across populations and disease phenotypes. According to Glycogen Storage Disease Type II (Pompe Disease) Epidemiology Forecast by Expert Market Research (EMR), Pompe disease remains an underdiagnosed inherited metabolic disorder, with increasing clinical recognition, newborn screening, molecular diagnosis and development of enzyme replacement and next-generation therapies shaping the evolving disease landscape.

2025

Base Year

2019-2025

Historical Period

2026-2035

Forecast Period

Glycogen Storage Disease Type II (Pompe Disease) – Number of Cases by Year

Read more about this report - Request a Free Sample

Glycogen Storage Disease Type II (Pompe Disease) Epidemiology Forecast Report Coverage

Expert Market Research's “Glycogen Storage Disease Type II (Pompe Disease) Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of Glycogen Storage Disease Type II (Pompe Disease). It projects the future incidence and prevalence rates of Glycogen Storage Disease Type II (Pompe Disease) cases across various populations. The study covers age, gender, and type as major determinants of the Glycogen Storage Disease Type II (Pompe Disease) population. The report highlights patterns in the prevalence of Glycogen Storage Disease Type II (Pompe Disease) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of Glycogen Storage Disease Type II (Pompe Disease) in the 8 major markets.

Regions Covered

  • United States
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Glycogen Storage Disease Type II (Pompe Disease) Understanding: Disease Overview

Pompe disease, also known as glycogen storage disease type II (GSD II), acid maltase deficiency, or acid alpha-glucosidase (GAA) deficiency, is a rare inherited lysosomal storage disorder caused by pathogenic variants in the GAA gene. The disease follows an autosomal recessive inheritance pattern and results from deficient activity of lysosomal acid alpha-glucosidase, the enzyme responsible for hydrolyzing glycogen within lysosomes. Insufficient GAA activity leads to progressive intralysosomal glycogen accumulation, particularly in skeletal muscle, cardiac muscle, and respiratory muscle, ultimately causing cellular dysfunction and tissue damage.

Key Report Insights

Parameter

Insight

Largest Patient Pool

United States

Fastest Growing Country

France

High-Risk Population

Infants and children born to two carriers of pathogenic GAA variants, particularly those from families with a previous child affected by Pompe disease, constitute the highest-risk population.

Key Diagnostic Method

Acid alpha-glucosidase (GAA) enzyme activity assay, typically initiated using a dried blood spot (DBS) test and confirmed by enzyme testing in leukocytes/lymphocytes and/or molecular genetic testing of the GAA gene.

Major Risk Factor

Inheritance of pathogenic biallelic GAA variants: Pompe disease is an autosomal recessive disorder, and disease develops when an individual inherits pathogenic variants in both copies of the GAA gene.

Major gap in the market

Delayed diagnosis and limited access to comprehensive newborn screening.

Glycogen Storage Disease Type II (Pompe Disease) Epidemiology Perspective

The Glycogen Storage Disease Type II (Pompe Disease) epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the Glycogen Storage Disease Type II (Pompe Disease) epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Glycogen Storage Disease Type II (Pompe Disease) and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

Pompe disease has an estimated global prevalence of approximately 1 in 40,000 people, although population-based newborn-screening studies have reported substantially higher frequencies, reflecting previously undiagnosed infantile- and late-onset cases. Diagnosed prevalence therefore remains lower than the likely underlying prevalence because of delayed recognition and incomplete case ascertainment. Recent screening studies have reported birth prevalences around 1 in 18,000–20,000 births in some populations.

Gender-Specific Cases of the Disease

Pompe disease is an autosomal recessive disorder and is expected to affect males and females at approximately equal frequencies. Large registry data support this pattern: among 1,079 patients in the international Pompe Registry, 527 (48.8%) were male and 552 (51.2%) were female, indicating no meaningful overall sex predominance.

Age-Specific Cases of the Disease

Pompe disease can present at any age, but cases are broadly distributed between infantile-onset and late-onset disease. In the international Pompe Registry, classic infantile-onset disease was defined by symptom onset within the first 12 months with cardiomyopathy; these patients had a mean symptom-onset age of 0.2 years (2.4 months) and mean diagnosis age of 0.3 years (3.5 months). Patients with childhood/juvenile onset had a mean symptom-onset age of 4.0 years, whereas those with onset after 12 years had a mean symptom-onset age of 36.5 years and mean diagnosis age of 42.8 years.

Ethnicity-Wise Cases of the Disease

A large population-genomic analysis estimated the highest predicted genetic prevalence in East Asian populations (approximately 1 in 12,125), followed by Non-Finnish Europeans (1 in 13,756), Ashkenazi Jewish populations (1 in 22,851), African/African-American populations (1 in 26,560), Latino/Admixed American populations (1 in 57,620), South Asian populations (1 in 93,087), and Finnish populations (1 in 1,056,444).

Mortality and Survival Analysis of the Disease

The prognosis of late-onset Pompe disease (LOPD) is considerably more heterogeneous and generally more prolonged. Progressive respiratory muscle weakness is a major determinant of morbidity and mortality. In the 2023 French Pompe Registry analysis, 35 of 210 adult patients died during follow-up; their mean age at death was 66.0 years, and 60% of recorded deaths were attributed to respiratory failure. Most deceased patients required ventilatory assistance, highlighting respiratory insufficiency as the principal disease-related determinant of mortality.

Type-Specific Disease Burden and Epidemiology Analysis

Disease Type

Prevalence

Infantile-Onset Pompe Disease (IOPD)

Pompe disease presenting during infancy. Classic IOPD is characterized by onset within the first year of life, profound hypotonia and muscle weakness, and hypertrophic cardiomyopathy/cardiac involvement. A non-classic infantile phenotype can present during infancy without the severe cardiomyopathy of classic IOPD.

Late-Onset Pompe Disease (LOPD)

Pompe disease presenting after infancy, including childhood, juvenile, adolescent and adult-onset disease. It is predominantly characterized by progressive skeletal and respiratory muscle weakness, with cardiac involvement generally less prominent than in classic IOPD.

Glycogen Storage Disease Type II (Pompe Disease) – Number of Cases by Country

Read more about this report - Request a Free Sample

Country-wise Glycogen Storage Disease Type II (Pompe Disease) Epidemiology

The Glycogen Storage Disease Type II (Pompe Disease) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Country

Key Insights

United States

The most appropriate current U.S. epidemiological estimate comes from newborn-screening data rather than extrapolating the older 1 in 40,000 estimate. An analysis covering 9,794,141 U.S. newborns screened across 22 states from 2010-2022 identified 522 confirmed Pompe disease cases, corresponding to a birth prevalence of approximately 1 in 18,763 births. Of these, 63 were classified as infantile-onset Pompe disease (IOPD) and 459 as late-onset Pompe disease (LOPD).

Germany

Germany’s routine newborn-screening programme does not currently provide a nationwide Pompe-specific prevalence figure comparable with the U.S. dataset. Recent German NBS research has evaluated Pompe among candidate conditions, but the available publications do not establish a national Pompe birth prevalence.

France

The strongest France-specific epidemiological evidence is therefore the French National Pompe Registry. A recent analysis of the registry reported 246 genetically characterized Pompe patients, with late-onset Pompe disease (LOPD) diagnoses increasing from 2.6 per year before 2001 to 10.6/year during 2001-2010 and 12.8/year during 2011-2015, demonstrating substantial expansion of case ascertainment rather than providing a population prevalence denominator.

Italy

Italy has one of the stronger country-specific Pompe epidemiology datasets among the 8MM because of regional newborn-screening programmes. The best established estimate is from North-East Italy, where 206,741 newborns were screened over seven years. The study identified an overall Pompe disease incidence of 1 in 18,795 births, comprising 1 in 68,914 for infantile-onset Pompe disease (IOPD) and 1 in 25,843 for late-onset Pompe disease (LOPD).

Spain

A 2024 publication analyzing the Spanish Pompe Registry included 122 genetically characterized patients: 9 with infantile-onset Pompe disease (IOPD) and 113 with late-onset Pompe disease (LOPD). The authors estimated the prevalence of diagnosed Pompe disease in Spain at approximately 3.1 cases per million inhabitants (3.1/1,000,000). They also reported substantial regional variation, with the highest prevalence observed in Andalusia.

United Kingdom

For the United Kingdom, the best recent country-specific estimate is approximately 1 in 40,000 people for Pompe disease prevalence. This figure is cited in the first UK-specific clinical consensus review published in 2025. The same review estimates that 35-40 children in the UK are living with infantile-onset Pompe disease (IOPD).

Japan

Approximately 1 in 37,094 live births, based on Japanese newborn-screening data from 296,759 births; IOPD was detected at approximately 1 in 296,759 births, while additional potential LOPD cases were identified. The estimate is based on regional/participating screening programmes rather than nationwide population surveillance.

India

A 2024 study from an Indian tertiary genetic centre identified 78 biochemically diagnosed Pompe patients, including only 3 adult-onset cases; this is a centre-based case series and cannot be converted into national prevalence. There is also a prospective Indian study of 45 clinically suspected high-risk children, in which genetically confirmed Pompe disease was identified in approximately 8.8%. However, this is a high-risk clinical cohort, not population prevalence, and therefore should not be reported as India's prevalence.

Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape

The Pompe disease epidemiology landscape across the 8MM remains constrained by substantial underdiagnosis, delayed recognition of late-onset disease, and uneven access to confirmatory GAA enzyme and molecular testing. The absence of universal newborn screening in several countries, particularly India and France, limits early identification of affected infants and presymptomatic patients. Expansion of newborn screening standardized diagnostic algorithms, genetic testing, and specialist referral pathways represents a major opportunity to increase case detection. Growing recognition of late-onset Pompe disease among adults with unexplained proximal muscle weakness or respiratory insufficiency is also expected to expand the diagnosed patient pool. In parallel, improved national registries and cross-border epidemiological surveillance could address the current scarcity of reliable country-specific prevalence data, particularly in India, Germany, France, and Spain.

Glycogen Storage Disease Type II (Pompe Disease): Treatment Overview

The cornerstone of Pompe disease treatment is lifelong enzyme replacement therapy (ERT), which supplies recombinant acid alpha-glucosidase (GAA) to reduce lysosomal glycogen accumulation. Alglucosidase alfa was the first approved ERT and remains an established treatment, particularly for infantile-onset Pompe disease (IOPD). Avalglucosidase alfa, a next-generation ERT with enhanced mannose-6-phosphate receptor targeting, is also approved and can improve or stabilize motor and respiratory function. Cipaglucosidase alfa combined with miglustat provides another ERT option for late-onset Pompe disease (LOPD) in jurisdictions where approved.

Key Questions Answered

  • What is the current and projected burden of Glycogen Storage Disease Type II (Pompe Disease) across the 8 major markets?
  • Which countries across the 8 major markets account for the highest Glycogen Storage Disease Type II (Pompe Disease) patient populations and fastest growth rates?
  • What is the diagnosed versus undiagnosed patient population of Glycogen Storage Disease Type II (Pompe Disease) across key countries in the 8 major markets?
  • Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of Glycogen Storage Disease Type II (Pompe Disease) across the 8 major markets?
  • What are the major drivers contributing to the increasing burden of Glycogen Storage Disease Type II (Pompe Disease) across the 8 major markets?
  • How do major comorbidities and risk factors influence Glycogen Storage Disease Type II (Pompe Disease) epidemiology trends across the 8 major markets?
  • What are the regional trends in advanced disease progression, treatment uptake, and patient management of Glycogen Storage Disease Type II (Pompe Disease) across the 8 major markets?
  • Which patient segments represent the highest unmet clinical need in the Glycogen Storage Disease Type II (Pompe Disease) landscape across the 8 major markets?
  • Which therapeutic areas linked to Glycogen Storage Disease Type II (Pompe Disease) are expected to witness the strongest growth opportunities across the 8 major markets?
  • How is the Glycogen Storage Disease Type II (Pompe Disease) epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
  • Which countries across the 8 major markets offer the most attractive market opportunities based on Glycogen Storage Disease Type II (Pompe Disease) epidemiology and healthcare infrastructure?
  • Which epidemiological trends are expected to influence future drug development and market access strategies for Glycogen Storage Disease Type II (Pompe Disease) across the 8 major markets?

Scope of the Glycogen Storage Disease Type II (Pompe Disease) Epidemiology Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Glycogen Storage Disease Type II (Pompe Disease) based on several factors.
  • Glycogen Storage Disease Type II (Pompe Disease) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The Glycogen Storage Disease Type II (Pompe Disease) report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Iron Deficiency Anemia Epidemiology Forecast

Alpha-1 Antitrypsin Deficiency AATD Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Report Features

Details

Base Year

2025

Historical Period

2019-2025

Forecast Period

2026-2035

Epidemiology Statistics Provided

  • Diagnosed Prevalent Cases
  • Type-Specific Cases
  • Gender-Specific Cases
  • Age-Specific Cases

Segmentation Provided

  • Epidemiology by Age Group
  • Epidemiology by Gender
  • Epidemiology by Type of Disease
  • Epidemiology by Region

Geographies Covered

  • United States
  • Germany
  • Italy
  • France
  • Spain
  • United Kingdom
  • Japan
  • India

Datasheet

10 % Off

USD

2,699

2,429

Single User License

10 % Off

USD

4,299

3,869

Five User License

15 % Off

USD

5,799

4,949

Corporate License

15 % Off

USD

6,999

5,949

Datasheet

One User

USD 2,699

USD 2,429

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 4,299

USD 3,869

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 5,799

USD 4,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us